AU Patent

AU2017203817B2 — Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof

Assigned to F Hoffmann La Roche AG · Expires 2018-10-18 · 8y expired

What this patent protects

-71 Abstract The present invention relates to crystalline polymorphs of (2-(4-(2-(1-isopropyl-3-methyl-1H 1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2 methylpropanamide (GDC-0032, taselisib), methods of use, and processes of preparin…

USPTO Abstract

-71 Abstract The present invention relates to crystalline polymorphs of (2-(4-(2-(1-isopropyl-3-methyl-1H 1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2 methylpropanamide (GDC-0032, taselisib), methods of use, and processes of preparing thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017203817B2
Jurisdiction
AU
Classification
—
Expires
2018-10-18
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.